Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 10/20 | 0.57 |
| ▸ | FLT1 known ✓ | P17948 | 6/20 | 0.57 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.56 |
| ▸ | CSF1R known ✓ | P07333 | 1/20 | 0.56 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.56 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.56 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.56 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.56 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.56 |
| ▸ | PDE5A known ✓ | O76074 | 1/20 | 0.48 |
| ▸ | GOT1 | P17174 | 1/20 | 0.56 |
| ▸ | CIT | O14578 | 1/20 | 0.56 |
| ▸ | HLA-A | P04439 | 1/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.56 |
| ▸ | FRK | P42685 | 1/20 | 0.56 |
| ▸ | CDK8 | P49336 | 1/20 | 0.56 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.56 |
| ▸ | STK3 | Q13188 | 1/20 | 0.56 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.56 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496240 | 0.98 | KDR (0.58) | KDRFLT1GOT1CITEGFR | |
| SCHEMBL10338919 | 0.87 | GOT1 (0.61) | KDRFLT1GOT1CITEGFR | |
| SCHEMBL6505060 | 0.82 | MAPT (0.57) | KDRFLT1GOT1CITEGFR | |
| SCHEMBL3759288 | 0.81 | KDR (0.63) | KDRSMN1; SMN2NPC1RAB9AENPP3 | |
| SCHEMBL4738808 | 0.80 | PDE5A (0.69) | KDRGOT1EGFRSMN1; SMN2NPC1 | |
| SCHEMBL7915165 | 0.79 | ALDH1A1 (0.72) | KDRFLT1CITEGFRHLA-A | |
| Hydrochloric Acid SCHEMBL1831909 | 0.76 | GAA (0.84) | KDRSMN1; SMN2ENPP3PDE5AKDM4E | |
| SCHEMBL7913416 | 0.76 | NPSR1 (0.73) | KDRSMN1; SMN2ENPP3PDE5AKDM4E | |
| SCHEMBL31359772 | 0.74 | MAPT (0.64) | KDRFLT1GOT1EGFRRET | |
| SCHEMBL26118348 | 0.74 | MAPT (0.64) | KDRFLT1GOT1EGFRRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903101-B1 | Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-07 | — | — | US | disclosed |
| EP-0970070-B1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2004-10-06 | — | — | EP | disclosed |
| EP-1208096-B1 | SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER AG (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6710047-B2 | INHIBIT THE ACTIVITY OF THE VEGF RECEPTOR TYROSINE KINASE AND THE GROWTH OF TUMOURS | NOVARTIS AG (CH) | 2004-03-23 | — | — | US | disclosed |
| US-20030191129-A1 | Phthalazines with angiogenesis inhibiting activity | BOLD GUIDO (CH) | 2003-10-09 | — | — | US | disclosed |
| US-6514974-B2 | 1-(4-Chloroanilino)-4-(4-pyridylmethyl)phthalazine for example | NOVARTIS AG (CH) | 2003-02-04 | — | — | US | disclosed |
| US-20020091261-A1 | Phthalazines with angiogenesis inhibiting activity | BOLD GUIDO (CH) | 2002-07-11 | — | — | US | disclosed |
| EP-1208096-A1 | SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | Bayer Corporation (US) | 2002-05-29 | — | — | EP | disclosed |
| US-6258812-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS AND CARDIOVASCULAR DISORDERS | NOVARTIS AG (CH) | 2001-07-10 | — | — | US | disclosed |
| WO-2001010859-A1 | SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORPORATION (US) | 2001-02-15 | — | — | WO | disclosed |
| EP-0970070-A1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | Novartis AG (CH) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998035958-A1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191129-A1 | Phthalazines with angiogenesis inhibiting activity | PGF, VEGFA, FLT4 | KDR 10/4885FLT1 4/4885EGFR 1872/4885 |
| US-20020091261-A1 | Phthalazines with angiogenesis inhibiting activity | PGF, VEGFA, FLT4 | KDR 16/4885FLT1 4/4885EGFR 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.